Literature DB >> 1984467

Antimicrobial activity of an abundant calcium-binding protein in the cytoplasm of human neutrophils.

P G Sohnle1, C Collins-Lech, J H Wiessner.   

Abstract

Studies of experimental infections in animals indicate that phagocytic cells may sometimes control infective foci without actually ingesting or contacting the invading microorganisms. In the present study, an effective inhibitor of Candida albicans growth, previously detected in neutrophils cytoplasm and found to be released only after lysis of the cells, was identified as an abundant calcium-binding protein originally described in neutrophils as the L1 myelomonocytic antigen or the cystic fibrosis antigen. This substance was demonstrated also to have static activity against several other important human pathogens, including Aspergillus fumigatus, Staphylococcus aureus, and Escherichia coli. Growth of the various microorganisms was inhibited to considerably different degrees by the neutrophil protein, with the effects on S. aureus (the least responsive organism) being significantly enhance by addition of calcium to the medium. These findings suggest that after its release by the death of neutrophils at sites of tissue infection, this abundant calcium-binding protein could have a host defense function by controlling the growth of pathogenic microorganisms that escape being killed initially and would otherwise be free to proliferate.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1984467     DOI: 10.1093/infdis/163.1.187

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  44 in total

1.  MRP 8/14 as marker for Plasmodium falciparum-induced malaria episodes in individuals in a holoendemic area.

Authors:  G Bordmann; G Burmeister; S Saladin; H Urassa; S Mwankyusye; N Weiss; M Tanner
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

Review 2.  Metal ion acquisition in Staphylococcus aureus: overcoming nutritional immunity.

Authors:  James E Cassat; Eric P Skaar
Journal:  Semin Immunopathol       Date:  2011-11-03       Impact factor: 9.623

3.  Nomenclature for proteins: is calprotectin a proper name for the elusive myelomonocytic protein?

Authors:  M K Fagerhol
Journal:  Clin Mol Pathol       Date:  1996-04

4.  Initial Biochemical and Functional Evaluation of Murine Calprotectin Reveals Ca(II)-Dependence and Its Ability to Chelate Multiple Nutrient Transition Metal Ions.

Authors:  Rose C Hadley; Yu Gu; Elizabeth M Nolan
Journal:  Biochemistry       Date:  2018-05-02       Impact factor: 3.162

Review 5.  Functional and clinical aspects of the myelomonocyte protein calprotectin.

Authors:  B Johne; M K Fagerhol; T Lyberg; H Prydz; P Brandtzaeg; C F Naess-Andresen; I Dale
Journal:  Mol Pathol       Date:  1997-06

6.  The middle ear immune defense changes with age.

Authors:  Michelle Christine Nielsen; Morten Friis; Tomas Martin-Bertelsen; Ole Winther; Lennart Friis-Hansen; Per Cayé-Thomasen
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-01-07       Impact factor: 2.503

7.  Calprotectin as a diagnostic tool for inflammatory bowel diseases.

Authors:  Marianthi Chatzikonstantinou; Panagiotis Konstantopoulos; Spyros Stergiopoulos; Konstantinos Kontzoglou; Christos Verikokos; Despina Perrea; Dimitris Dimitroulis
Journal:  Biomed Rep       Date:  2016-09-07

8.  Serum 27E10 antigen: a new potential marker for staging HIV disease.

Authors:  N Lügering; R Stoll; T Kucharzik; G Burmeister; C Sorg; W Domschke
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

9.  S100A8/A9 is not involved in host defense against murine urinary tract infection.

Authors:  Mark C Dessing; Loes M Butter; Gwendoline J Teske; Nike Claessen; Chris M van der Loos; Thomas Vogl; Johannes Roth; Tom van der Poll; Sandrine Florquin; Jaklien C Leemans
Journal:  PLoS One       Date:  2010-10-14       Impact factor: 3.240

10.  Fecal calprotectin excretion in preterm infants during the neonatal period.

Authors:  Carole Rougé; Marie-José Butel; Hugues Piloquet; Laurent Ferraris; Arnaud Legrand; Michel Vodovar; Marcel Voyer; Marie-France de la Cochetière; Dominique Darmaun; Jean-Christophe Rozé
Journal:  PLoS One       Date:  2010-06-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.